Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Influenza

  Free Subscription


Articles published in Drug Saf

Retrieve available abstracts of 26 articles:
HTML format



Single Articles


    November 2021
  1. CLINTON JW, Kiparizoska S, Aggarwal S, Woo S, et al
    Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature.
    Drug Saf. 2021;44:1125-1149.
    PubMed     Abstract available


  2. IGUCHI T, Umeda H, Kojima M, Kanno Y, et al
    Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
    Drug Saf. 2021;44:1209-1214.
    PubMed     Abstract available


    October 2021
  3. SALAMANCA DE LA CUEVA I, Cinconze E, Eckermann T, Nwoji U, et al
    Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
    Drug Saf. 2021 Oct 25. pii: 10.1007/s40264-021-01121.
    PubMed     Abstract available


    September 2021
  4. ROCCA E, Gauffin O, Savage R, Vidlin SH, et al
    Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Drug Saf. 2021;44:987-998.
    PubMed     Abstract available


  5. MOORE N, Bosco-Levy P, Thurin N, Blin P, et al
    NSAIDs and COVID-19: A Systematic Review and Meta-analysis.
    Drug Saf. 2021;44:929-938.
    PubMed     Abstract available


    June 2021
  6. BHOWMICK S, Dang A, Vallish BN, Dang S, et al
    Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.
    Drug Saf. 2021;44:635-644.
    PubMed     Abstract available


    April 2021
  7. DASGUPTA N
    Safety Consequences of Off-Label Drugs Used for COVID-19.
    Drug Saf. 2021;44:399-402.
    PubMed    


  8. GRANDVUILLEMIN A, Drici MD, Jonville-Bera AP, Micallef J, et al
    French Pharmacovigilance Public System and COVID-19 Pandemic.
    Drug Saf. 2021;44:405-408.
    PubMed     Abstract available


    February 2021
  9. MARZOLINI C, Stader F, Leuppi-Taegtmeyer A, Stoeckle M, et al
    Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.
    Drug Saf. 2021;44:255-257.
    PubMed    


    January 2021
  10. BEYZAROV E, Chen Y, Julg R, Naim K, et al
    Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
    Drug Saf. 2021;44:95-105.
    PubMed     Abstract available


  11. SHAKIR S, Lane S, Davies M
    How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.
    Drug Saf. 2021;44:1-5.
    PubMed    


    December 2020
  12. GARCIA P, Revet A, Yrondi A, Rousseau V, et al
    Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Drug Saf. 2020;43:1315-1322.
    PubMed     Abstract available


  13. PETOUSIS-HARRIS H
    Assessing the Safety of COVID-19 Vaccines: A Primer.
    Drug Saf. 2020;43:1205-1210.
    PubMed     Abstract available


  14. ZEKARIAS A, Watson S, Vidlin SH, Grundmark B, et al
    Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Drug Saf. 2020;43:1309-1314.
    PubMed     Abstract available


  15. TRIFIRO G, Massari M, Da Cas R, Menniti Ippolito F, et al
    Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Drug Saf. 2020;43:1297-1308.
    PubMed     Abstract available


    August 2020
  16. OSBORNE V, Davies M, Lane S, Evans A, et al
    Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
    Drug Saf. 2020;43:809-821.
    PubMed     Abstract available


  17. SULTANA J, Cutroneo PM, Crisafulli S, Puglisi G, et al
    Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
    Drug Saf. 2020;43:691-698.
    PubMed     Abstract available


  18. TUCCORI M, Convertino I, Ferraro S, Cappello E, et al
    The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.
    Drug Saf. 2020;43:699-709.
    PubMed     Abstract available


    July 2020
  19. MOORE N, Carleton B, Blin P, Bosco-Levy P, et al
    Does Ibuprofen Worsen COVID-19?
    Drug Saf. 2020;43:611-614.
    PubMed    


  20. OLRY A, Meunier L, Delire B, Larrey D, et al
    Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.
    Drug Saf. 2020;43:615-617.
    PubMed    


  21. MONTASTRUC JL, Toutain PL
    A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.
    Drug Saf. 2020;43:657-660.
    PubMed     Abstract available


  22. DAVIES M, Osborne V, Lane S, Roy D, et al
    Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.
    Drug Saf. 2020;43:645-656.
    PubMed     Abstract available


    June 2020
  23. CHANDLER RE, McCarthy D, Delumeau JC, Harrison-Woolrych M, et al
    The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic.
    Drug Saf. 2020;43:511-512.
    PubMed    


  24. TRIFIRO G, Crisafulli S, Ando G, Racagni G, et al
    Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
    Drug Saf. 2020;43:507-509.
    PubMed    


    May 2020
  25. MOORE N
    Chloroquine for COVID-19 Infection.
    Drug Saf. 2020;43:393-394.
    PubMed    


    December 2019
  26. DOS SANTOS G, Nguyen BY, Damaso S, Godderis L, et al
    Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
    Drug Saf. 2019 Dec 28. pii: 10.1007/s40264-019-00893.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: